Dosage Forms And Routes - NAPLEX

1. A 62-year-old man (weight 85 kg) with benign prostatic hyperplasia is prescribed tamsulosin but reports he cannot swallow capsules and asks if he can open them. Medical history: benign prostatic hyperplasia, hypertension; allergies: none. Current medications (forms/routes): tamsulosin 0.4 mg capsule by mouth daily (new), hydrochlorothiazide 25 mg tablet by mouth daily. Labs: serum creatinine 1.0 mg/dL, AST/ALT within normal limits. Which dosage form is most appropriate for this patient to avoid altering a modified-release product and still treat symptoms?
   Answer: Switch to finasteride 5 mg tablet by mouth daily This question evaluates alternatives to modified-release capsules for BPH in patients with swallowing issues. The key patient-specific factor is inability to swallow capsules, and tamsulosin capsules should not be opened due to modified-release properties. Switching to finasteride tablets is the best as it provides an alternative BPH treatment in tablet form that can be swallowed or crushed if needed, avoiding alteration of tamsulosin. Opening or crushing tamsulosin risks uncontrolled release; tamsulosin tablets are not available. Avoid manipulating extended-release products to prevent dosing errors. Factor in age, symptoms, and formulation integrity for urologic medications.
2. A 33-year-old man (weight 78 kg) with seasonal allergic rhinitis wants a non-sedating option with rapid onset for nasal congestion and sneezing. Medical history: none; allergies: none. Current medications (forms/routes): cetirizine 10 mg tablet by mouth daily as needed (causes drowsiness). Labs: not applicable. Which dosage form is most appropriate to target symptoms locally and minimize systemic sedation?
   Answer: Fluticasone nasal spray, 2 sprays in each nostril once daily This question tests the choice of antihistamine or corticosteroid dosage forms for allergic rhinitis to minimize sedation. The key patient-specific factor is the patient's desire for non-sedating relief with rapid onset for nasal symptoms, having experienced drowsiness with cetirizine. Fluticasone nasal spray is the best choice as it delivers targeted intranasal corticosteroids, reducing congestion locally with minimal systemic absorption and sedation. Oral diphenhydramine and cetirizine cause sedation; systemic prednisone increases side effect risks unnecessarily. For localized allergic symptoms, intranasal forms provide effective, low-systemic therapy. Assess patient age, symptom severity, and preferences when selecting allergy treatments.
3. A 36-year-old woman (weight 69 kg) with acute bacterial conjunctivitis requests treatment and prefers to avoid systemic antibiotics. Medical history: none; allergies: sulfonamides (rash). Current medications (forms/routes): none. Labs: not applicable. Which dosage form is most appropriate to deliver medication directly to the site of infection?
   Answer: Erythromycin ophthalmic ointment applied to affected eye(s) This question tests selecting targeted dosage forms for ocular infections to avoid unnecessary systemic exposure. The key patient-specific factor is the patient's preference to avoid systemic antibiotics for localized conjunctivitis. Erythromycin ophthalmic ointment is the best as it delivers medication directly to the eye, minimizing systemic side effects. Oral, IM, or transdermal routes provide unneeded systemic exposure. Topical ocular forms are ideal for superficial eye infections. Consider allergy history and infection site in antimicrobial selection.
4. A 55-year-old man (weight 95 kg) with COPD presents with hoarseness and white patches in the mouth after starting a new inhaler 3 weeks ago. Medical history: COPD, hyperlipidemia; allergies: none. Current medications (forms/routes): fluticasone/salmeterol 250/50 mcg dry powder inhaler 1 inhalation by mouth twice daily, albuterol HFA inhaler 2 puffs by mouth every 4–6 hours as needed, atorvastatin 20 mg tablet by mouth nightly. Labs: serum creatinine 1.1 mg/dL, AST/ALT within normal limits. Which counseling point is most important for this dosage form to reduce the adverse effect he is experiencing?
   Answer: Rinse mouth and spit after each fluticasone/salmeterol dose This question assesses strategies to mitigate local adverse effects associated with inhaled corticosteroid dosage forms in COPD management. The key patient-specific factor is the development of oral thrush (white patches) and hoarseness, likely due to oropharyngeal deposition of fluticasone from the dry powder inhaler. Rinsing the mouth and spitting after each dose is the best choice as it removes residual medication from the oral cavity, reducing the risk of thrush without altering systemic efficacy. Using a spacer with a dry powder inhaler is incorrect because spacers are typically for metered-dose inhalers, not dry powder; swallowing water after dosing may not adequately clear the mouth and could increase gastrointestinal absorption; switching to nebulized fluticasone is unnecessary and may increase systemic exposure. In patients using inhaled corticosteroids, always emphasize post-inhalation oral hygiene to prevent candidiasis. Consider patient technique and device type when troubleshooting inhaler-related issues to optimize therapy.
5. A 27-year-old woman (weight 64 kg) is prescribed clindamycin for acne but reports severe diarrhea after starting oral capsules. Medical history: acne; allergies: none. Current medications (forms/routes): clindamycin 300 mg capsules by mouth twice daily (started 5 days ago), benzoyl peroxide wash topical daily. Labs: serum creatinine 0.8 mg/dL, AST/ALT within normal limits. Which action should the pharmacist take regarding administration route to reduce systemic adverse effects while treating acne?
   Answer: Switch to topical clindamycin gel or solution applied to affected areas This question examines switching antibiotic routes for acne to minimize systemic side effects. The key patient-specific factor is severe diarrhea from oral clindamycin, indicating gastrointestinal intolerance. Switching to topical clindamycin is the best as it targets skin directly, reducing systemic exposure and diarrhea risk. Continuing oral with loperamide masks symptoms; IV or topical powder misuse is inappropriate. Topical forms are preferred for dermatologic conditions to limit adverse effects. Consider disease site and patient tolerance when selecting antimicrobial routes.
6. A 70-year-old woman (weight 60 kg) with osteoporosis has been prescribed alendronate but reports she is non-adherent because she cannot follow the administration instructions and often lies down soon after taking morning medications. Medical history: osteoporosis, GERD; allergies: none. Current medications (forms/routes): alendronate 70 mg tablet by mouth once weekly (misses), calcium carbonate 500 mg chewable tablet by mouth twice daily, pantoprazole 40 mg tablet by mouth daily. Labs: serum creatinine 0.9 mg/dL, AST/ALT within normal limits. What adjustment is needed for this patient's medication regimen to address adherence related to complex administration?
   Answer: Switch to intravenous zoledronic acid once yearly administered in clinic This question examines alternatives to oral bisphosphonates for osteoporosis to overcome adherence barriers from complex instructions. The key patient-specific factor is the patient's non-adherence due to inability to follow fasting and upright positioning requirements, exacerbated by GERD. Switching to intravenous zoledronic acid once yearly is the best choice as it simplifies administration via clinic infusion, eliminating daily/weekly oral constraints and reducing esophageal risks. Increasing oral dosing or crushing tablets heightens irritation; changing to multiple daily doses complicates further. For patients with adherence issues to oral bisphosphonates, parenteral options improve compliance. Factor in age, comorbidities like GERD, and lifestyle for osteoporosis therapy selection.
7. A 50-year-old man (weight 88 kg) with opioid use disorder is stable on buprenorphine/naloxone sublingual films but reports he has been swallowing the film immediately because he dislikes the taste and wants it to work faster. Medical history: opioid use disorder; allergies: none. Current medications (forms/routes): buprenorphine/naloxone 8 mg/2 mg sublingual film once daily, sertraline 50 mg tablet by mouth daily. Labs: AST/ALT within normal limits, serum creatinine 0.9 mg/dL. What counseling point is most important for this dosage form?
   Answer: Place the film under the tongue and allow it to dissolve completely; avoid eating or drinking until dissolved This question tests counseling on sublingual film administration for opioid use disorder to ensure proper absorption. The key patient-specific factor is the patient's habit of swallowing the film immediately, reducing sublingual absorption and efficacy. Placing under the tongue to dissolve completely, avoiding food/drink, is the best as it maximizes mucosal absorption and prevents reduced bioavailability. Swallowing, chewing, or dissolving in water decreases effectiveness. Proper technique is vital for sublingual formulations to achieve therapeutic levels. Tailor counseling to patient preferences and monitor for misuse in addiction therapy.
8. A 38-year-old man (weight 86 kg) presents to urgent care with an acute migraine rated 9/10 with significant nausea and vomiting. Medical history: migraines; allergies: none. Current medications (forms/routes): sumatriptan 100 mg tablets by mouth as needed (vomits after dosing), ondansetron 4 mg orally disintegrating tablet by mouth as needed, multivitamin tablet by mouth daily. Labs: serum creatinine 1.0 mg/dL, AST/ALT within normal limits. What is the best route of administration to provide faster and more reliable onset for abortive migraine therapy in this patient today?
   Answer: Sumatriptan 6 mg subcutaneous injection at onset of migraine This question evaluates the optimal route for abortive migraine therapy when oral administration is compromised. The key patient-specific factor is the patient's significant nausea and vomiting during migraines, causing him to vomit after taking oral sumatriptan tablets. Sumatriptan subcutaneous injection is the best choice as it provides the fastest onset (within 10-15 minutes) and bypasses the gastrointestinal tract, ensuring reliable absorption despite vomiting. Oral tablets are suboptimal due to delayed absorption and risk of vomiting the dose; intranasal spray may be affected by nasal congestion or incomplete absorption during nausea; repeated oral dosing every 2 hours risks exceeding maximum daily limits and does not address vomiting. For patients with migraines accompanied by severe gastrointestinal symptoms, non-oral routes like subcutaneous or intranasal are preferable to achieve rapid relief. Pharmacists should counsel on proper injection technique and monitor for side effects like injection site reactions.
9. A 59-year-old woman (weight 77 kg) has chronic stable angina and reports frequent headaches and skin irritation where she applies her nitroglycerin patch. Medical history: coronary artery disease, hypertension; allergies: none. Current medications (forms/routes): nitroglycerin transdermal patch 0.4 mg/hour applied daily (she leaves it on 24 hours), aspirin 81 mg tablet by mouth daily, metoprolol tartrate 50 mg tablet by mouth twice daily. Labs: serum creatinine 0.9 mg/dL, AST/ALT within normal limits. What counseling point is most important for this dosage form to reduce tolerance and improve safety?
   Answer: Use a daily nitrate-free interval (e.g., remove patch for 10–12 hours) and rotate application sites This question assesses proper use of transdermal nitroglycerin to prevent tolerance and adverse effects in angina. The key patient-specific factor is the patient's continuous 24-hour patch use, causing headaches and potential tolerance, plus site irritation. Using a nitrate-free interval and rotating sites is the best as it prevents tolerance and reduces skin issues. Continuous wear promotes tolerance; same-site application worsens irritation; cutting patches alters dosing. Nitrate-free periods are key for transdermal antianginals to maintain efficacy. Consider patient condition and daily routine in cardiovascular therapy planning.
10. A 63-year-old man (weight 80 kg) with Parkinson disease reports difficulty swallowing and frequent choking, and his tremor worsens when he misses doses. Medical history: Parkinson disease, GERD; allergies: none. Current medications (forms/routes): carbidopa/levodopa 25/100 mg immediate-release tablets by mouth three times daily, omeprazole 20 mg capsule by mouth daily. Labs: serum creatinine 1.0 mg/dL, AST/ALT within normal limits. Which action should the pharmacist take regarding administration route to help maintain symptom control while addressing dysphagia?
    Answer: Recommend switching to carbidopa/levodopa orally disintegrating tablets by mouth This question examines adaptations to Parkinson medication dosage forms for patients with dysphagia to maintain symptom control. The key patient-specific factor is the patient's swallowing difficulty and choking, leading to missed doses and worsened tremors. Switching to carbidopa/levodopa orally disintegrating tablets is the best choice as they dissolve on the tongue, bypassing swallowing issues while providing equivalent dosing. Crushing extended-release tablets alters pharmacokinetics; intramuscular injections are not available for home use; stopping therapy ignores the underlying condition. For neurodegenerative diseases with dysphagia, orally disintegrating forms preserve efficacy and safety. Evaluate patient age, motor skills, and comorbidities when adapting antiparkinsonian regimens.
11. A 45-year-old man (weight 82 kg) with erectile dysfunction asks for a medication that works faster than his current therapy. Medical history: erectile dysfunction; allergies: none. Current medications (forms/routes): sildenafil 50 mg tablet by mouth as needed (takes with high-fat meals), atorvastatin 10 mg tablet by mouth nightly. Labs: serum creatinine 1.0 mg/dL, AST/ALT within normal limits. Which action should the pharmacist take regarding administration route or dosage form to improve onset?
    Answer: Counsel to take sildenafil on an empty stomach (avoid high-fat meals) to improve onset This question evaluates optimizing oral PDE5 inhibitor administration for faster onset in erectile dysfunction. The key patient-specific factor is the patient's intake with high-fat meals, delaying sildenafil absorption and onset. Counseling to take on an empty stomach is the best as it enhances bioavailability and speeds onset to 30-60 minutes. Intravenous or topical use is not indicated; extended-release does not improve as-needed timing. Food interactions significantly affect oral ED medications' pharmacokinetics. Assess lifestyle factors like meal timing when counseling on as-needed therapies.
12. A 24-year-old woman (weight 58 kg) requests emergency contraception and states she has severe nausea with pills and difficulty swallowing tablets. Medical history: none; allergies: none. Current medications (forms/routes): none. Labs: not available; pregnancy test is negative today. Which dosage form is most appropriate to provide effective emergency contraception while avoiding an oral tablet?
    Answer: Copper intrauterine device placed in clinic within 5 days of unprotected intercourse This question tests the selection of emergency contraception dosage forms for patients with oral administration challenges. The key patient-specific factor is the patient's severe nausea with pills and difficulty swallowing tablets, making oral options unreliable. The copper intrauterine device placed within 5 days is the best choice as it provides highly effective, non-oral contraception without relying on gastrointestinal absorption. Oral tablets like levonorgestrel, ulipristal, or ethinyl estradiol/norgestrel are suboptimal due to the risk of vomiting or swallowing issues, potentially reducing efficacy. For patients intolerant to oral medications, non-systemic options like IUDs offer reliable alternatives. Always confirm negative pregnancy tests and counsel on insertion timing and potential side effects.
13. A 58-year-old man (weight 102 kg) with type 2 diabetes reports burning and redness at his injection sites after starting insulin glargine pens; he injects into the same spot on his abdomen every night. Medical history: type 2 diabetes; allergies: none. Current medications (forms/routes): insulin glargine 30 units subcutaneous nightly via prefilled pen, metformin 1000 mg tablet by mouth twice daily. Labs: A1c 7.8%, serum creatinine 0.9 mg/dL, AST/ALT within normal limits. Which counseling point is most important for this dosage form to reduce local adverse effects?
    Answer: Rotate subcutaneous injection sites to reduce lipodystrophy and irritation This question evaluates strategies to minimize local adverse effects from injectable insulin dosage forms. The key patient-specific factor is the patient's repeated injections into the same abdominal site, causing burning and redness indicative of lipodystrophy. Rotating subcutaneous injection sites is the best choice as it prevents tissue damage and irritation, improving comfort and absorption consistency. Intradermal injection is incorrect and painful; indefinite room temperature storage risks insulin degradation; vigorous massage can cause bruising. Site rotation is essential for all injectable therapies to avoid complications. Consider patient education on technique and monitoring for signs of irritation in diabetes management.
14. A 52-year-old man (weight 90 kg) presents with severe acute postoperative pain and needs rapid analgesia; he is currently NPO (nothing by mouth). Medical history: hypertension; allergies: none. Current medications (forms/routes): hydromorphone 2 mg tablets by mouth as needed at home (not available inpatient), lisinopril 10 mg tablet by mouth daily (held due to NPO). Labs: serum creatinine 0.8 mg/dL, AST/ALT within normal limits. What is the best route of administration for opioid analgesia to achieve rapid onset in this patient?
    Answer: Intravenous opioid injection This question evaluates routes for opioid analgesia in patients unable to take oral medications postoperatively. The key patient-specific factor is the patient's NPO status, prohibiting oral intake and necessitating non-oral rapid-onset options. Intravenous opioid injection is the best choice as it provides the fastest onset (immediate) and titratable pain relief in an acute setting without gastrointestinal involvement. Oral tablets are impossible due to NPO; transdermal patches are for chronic pain and have delayed onset; rectal suppositories have variable absorption and slower onset than IV. In acute pain scenarios with NPO restrictions, intravenous routes ensure rapid and reliable analgesia. Consider patient monitoring for respiratory depression and transition to oral forms as soon as feasible.
15. A 40-year-old man (weight 75 kg) with gastroesophageal reflux disease reports persistent nighttime symptoms despite taking omeprazole 20 mg capsule by mouth daily; he admits he takes it after dinner. Medical history: GERD; allergies: none. Current medications (forms/routes): omeprazole 20 mg delayed-release capsule by mouth daily, calcium carbonate chewable tablets by mouth as needed. Labs: not applicable. What counseling point is most important for this dosage form to optimize efficacy?
    Answer: Take omeprazole 30–60 minutes before a meal (e.g., before breakfast) This question evaluates optimal timing for proton pump inhibitor dosage forms to maximize acid suppression in GERD. The key patient-specific factor is persistent symptoms due to taking omeprazole after dinner, misaligning with peak proton pump activity. Taking 30-60 minutes before breakfast is the best as it coincides with meal-stimulated acid production for better efficacy. Bedtime with snack, chewing granules, or as-needed use reduces effectiveness. Proper timing is crucial for delayed-release PPIs. Consider patient lifestyle and meal patterns in GI therapy counseling.
16. A 61-year-old woman (weight 74 kg) with atrial fibrillation on warfarin reports new gum bleeding and easy bruising after starting an over-the-counter product for joint pain. Medical history: atrial fibrillation, osteoarthritis; allergies: none. Current medications (forms/routes): warfarin 5 mg tablet by mouth daily, metoprolol succinate 50 mg extended-release tablet by mouth daily, diclofenac 1% topical gel applied to knees four times daily (started 1 week ago). Labs: INR 4.2, serum creatinine 1.0 mg/dL, AST/ALT within normal limits. Which factor should be considered when choosing a dosage form for pain in this patient?
    Answer: Systemic exposure can still occur with topical NSAIDs and may increase bleeding risk with warfarin This question explores the impact of NSAID dosage forms on drug interactions, particularly with anticoagulants like warfarin. The key patient-specific factor is the patient's use of warfarin, with new bleeding symptoms after starting topical diclofenac, indicating potential systemic effects. Recognizing that systemic exposure can occur with topical NSAIDs and may increase bleeding risk with warfarin is the best consideration, as it explains the elevated INR and guides safer alternatives. Claiming no systemic absorption is incorrect, as topical NSAIDs can be absorbed; rectal or intranasal forms do not necessarily bypass interactions and may still pose risks. Pharmacists should evaluate all routes for potential systemic effects when assessing drug interactions. In patients on anticoagulants, prefer non-NSAID topical options or monitor INR closely if NSAIDs are unavoidable.
17. A 29-year-old woman (weight 62 kg) is prescribed metronidazole for bacterial vaginosis but reports she keeps missing doses because the regimen is confusing and she dislikes taking pills. Medical history: none significant; allergies: none. Current medications (forms/routes): combined oral contraceptive tablet by mouth daily. Labs: serum creatinine 0.8 mg/dL, AST/ALT within normal limits, pregnancy test negative. The prescriber wrote metronidazole 500 mg tablets by mouth twice daily for 7 days. What adjustment is needed for this patient's medication regimen to improve adherence while remaining guideline-appropriate?
    Answer: Change to metronidazole 0.75% vaginal gel, 1 applicatorful intravaginally once daily for 5 days This question examines adjustments to antibiotic regimens for bacterial vaginosis to enhance adherence through simplified dosing and preferred routes. The key patient-specific factor is the patient's dislike of pills and confusion with multiple daily dosing, leading to missed doses. Metronidazole vaginal gel once daily for 5 days is the best choice as it simplifies administration to a single daily intravaginal dose, improving adherence while providing guideline-recommended local therapy. Changing to oral regimens with once-daily or multiple-daily dosing still involves pills, which the patient dislikes, and may not improve compliance; a 2 g once-daily oral dose is not standard for bacterial vaginosis. For infections amenable to topical treatment, consider patient preferences for non-oral routes to boost adherence. Always verify pregnancy status and counsel on proper applicator use for vaginal products.
18. A 67-year-old woman (weight 72 kg) presents for follow-up of chronic osteoarthritis knee pain (baseline pain 6/10) and reports she cannot reliably swallow tablets due to dysphagia after a prior stroke. Medical history includes osteoarthritis, hypertension, and ischemic stroke; allergies: ibuprofen (hives). Current medications (forms/routes): acetaminophen 500 mg tablets by mouth every 6 hours as needed (often skipped), lisinopril 20 mg tablet by mouth daily, atorvastatin 40 mg tablet by mouth nightly. Labs: serum creatinine 0.9 mg/dL, AST/ALT within normal limits, INR 1.0, A1c 5.6%. Which dosage form is most appropriate for this patient to improve acetaminophen use for pain control?
    Answer: Acetaminophen 500 mg effervescent powder packet dissolved in water by mouth every 6 hours as needed This question tests the selection of an appropriate acetaminophen dosage form for pain management in patients with swallowing difficulties. The key patient-specific factor is the patient's dysphagia due to a prior stroke, leading to skipped doses of oral tablets. Acetaminophen effervescent powder dissolved in water is the best choice because it provides a liquid form that is easier to swallow, improving adherence and pain control without requiring tablet ingestion. Extended-release tablets are suboptimal as they still require swallowing whole tablets, which the patient struggles with, and crushing them could alter release kinetics; rectal suppositories may be effective but are less convenient and acceptable for routine use in non-bedridden patients; crushed tablets mixed with water might help but can taste bitter and are not formulated for this purpose, potentially affecting palatability. When selecting dosage forms for analgesics in older adults with dysphagia, pharmacists should prioritize liquid or dissolvable options to enhance compliance and efficacy. Always consider the patient's overall medication regimen and allergies to avoid interactions or adverse effects.
19. A 73-year-old woman (weight 63 kg) with overactive bladder reports dry mouth and constipation on oxybutynin immediate-release tablets and frequently forgets her midday dose. Medical history: overactive bladder, constipation; allergies: none. Current medications (forms/routes): oxybutynin 5 mg tablet by mouth three times daily, polyethylene glycol powder by mouth daily as needed. Labs: serum creatinine 1.0 mg/dL, AST/ALT within normal limits. What adjustment is needed for this patient's medication regimen to reduce anticholinergic adverse effects and improve adherence?
    Answer: Switch to oxybutynin transdermal patch applied twice weekly This question assesses adjustments to anticholinergic medications for overactive bladder to reduce side effects and improve adherence. The key patient-specific factor is dry mouth, constipation, and forgotten doses with oral immediate-release oxybutynin. Switching to transdermal patch twice weekly is the best as it lowers anticholinergic burden via steady release and simplifies dosing. Increasing oral dose worsens effects; suppositories are not standard; adding diphenhydramine adds anticholinergics. Transdermal routes can enhance tolerability in geriatrics. Evaluate age, comorbidities, and dosing frequency for urinary therapies.
20. A 41-year-old woman (weight 66 kg) with asthma reports her rescue inhaler is not working quickly during attacks; review shows she uses her albuterol metered-dose inhaler without shaking, actuates multiple puffs at once, and does not inhale slowly. Medical history: asthma; allergies: none. Current medications (forms/routes): albuterol HFA metered-dose inhaler 2 puffs by mouth every 4–6 hours as needed, budesonide/formoterol inhaler 2 inhalations by mouth twice daily. Labs: not applicable. What counseling point is most important for this dosage form to optimize onset and delivery?
    Answer: Shake the inhaler, actuate 1 puff at a time, inhale slowly and deeply, and hold breath about 10 seconds This question assesses proper technique counseling for metered-dose inhalers to ensure effective drug delivery in asthma. The key patient-specific factor is the patient's incorrect technique, including not shaking, multiple actuations, and rapid inhalation, leading to poor symptom relief. Counseling to shake, actuate one puff, inhale slowly and deeply, and hold breath for 10 seconds is the best as it optimizes aerosol delivery and lung deposition for rapid onset. Inhaling quickly after actuation reduces deposition; storing in freezer or exhaling into the device can damage it or reduce dose. Proper inhaler technique is crucial for rescue medications to achieve quick bronchodilation. Tailor counseling to patient lifestyle and demonstrate techniques for better adherence.

Start this quiz